Mr. Peizer, the majority shareholder of BioVie, is an entrepreneur, investor, and financier with a particular interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a leader in behavioral and mental health management services, having served as the Company’s Chairman of the Board of Directors and CEO since the Company’s inception in 2003. Mr. Peizer also is the Founder, Chairman and CEO and majority shareholder of NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal holding company that owns his portfolio company interests. Through Acuitas, he owns Crede Capital Group, LLC, an industry leader in investing in micro and small capitalization public equities, having invested over $1.2 billion directly into portfolio companies. Previously he was Chairman of Cray, Inc., the leading supercomputing company, and held senior executive positions at various publicly-traded growth companies and with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in finance from The Wharton School of Finance and Commerce.
Steve Gorlin has founded many biotechnology and pharmaceutical companies over the past forty-five years, including Hycor Biomedical, Inc. (acquired by Agilent), Theragenics Corporation (NYSE: TGX) , Medicis Pharmaceutical Corporation (sold to Valeant for approximately $2.6 billion), EntreMed, Inc. (NASDAQ: ENMD), MRI Interventions (MRIC), DARA BioSciences, Inc. (NASDAQ: DARA), MiMedx (NASDAQ: MDXG), Medivation, Inc. (NASDAQ: MDVN), sold to Pfizer for $14 billion and Conkwest which became NantKwest (NASDAQ: NK). Mr. Gorlin served for many years on the Business Advisory Council to the Johns Hopkins School of Medicine and on The Johns Hopkins BioMedical Engineering Advisory Board. He also served on the Board of the Andrews Institute. He is currently a member of the Research Institute Advisory Committee (RIAC) of Massachusetts General Hospital. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children.
Bob Hariri, MD, PhD
Bob Hariri, MD, PhD, is the chairman, founder, and chief executive officer of Celularity, Inc., a leading human cellular therapeutics company. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. He has served on numerous public boards including Cryoport (NASDAQ:CYRX). Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues to make transformative contributions in the fields of immuno-oncology and cell therapeutics. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and assisting with the discovery of the physiological activities of tumor necrosis factor (TNF). He holds over 170 issued and pending patents and has authored over 150 published chapters, articles, and abstracts. Over the years he has garnered numerous awards for contributions to the fields of biomedicine and aviation.
Sig Rogich is President of The Rogich Communications Group and serves on the Board of Keep Memory Alive, a philanthropic organization which raises awareness about brain disorders and Alzheimer’s disease. Keep Memory Alive funds clinical trials through Cleveland Clinic’s Lou Ruvo Center for Brain Health to advance new treatments for patients with Alzheimer’s, Huntington’s and Parkinson’s disease, as well as frontotemporal dementia and multiple sclerosis. Mr. Rogich was formerly the US Ambassador to Iceland. He has served as a senior consultant to candidates for the highest office, including Presidents Ronald Reagan and George H.W. Bush. Mr. Rogich serves on the Board of Directors for many charitable causes.
President and Chief Executive Officer
Cuong Do, MBA, is President and CEO of BioVie Inc . Prior to his appointment with BioVie, Mr. Do was President of Samsung Global Strategy Group where he helped to set the strategic direction for Samsung Group’s diverse business portfolio. He was previously the Chief Strategy Officer for Merck, a leading US pharmaceuticals company. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years helping to build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.
Jim Lang, MBA, is the founder and CEO of EVERSANA™ which in just three short years has become the leading provider of global commercialization services to the life science industry. The company’s 3000+ employees serve over 600 life science organizations, including all top 25 biopharma. Under Mr. Lang’s leadership, EVERSANA™ will launch more biopharma products in each of the next few years than any other company. He formerly served as the CEO of Decision Resources Group (DRG). During his tenure, he transformed DRG into a leading healthcare data and analytics firm. Previously Mr. Lang was President of Strategic Decision Group (SDG) where he expanded the life sciences practice and later sold it to IQVia. He has served on numerous private and public boards, currently including HCIT leader OptimizeRx (OPRX). He has provided investment and guided the development of multiple early-stage healthcare companies including Boston Heart Labs and AlphaImpactRx. He holds a BS in electrical and computer engineering from the University of New Hampshire, and an MBA from the Tuck School of Business at Dartmouth. Mr. Lang was honored by PharmaVoice in 2020 as one of the “100 most inspiring people” in the industry.
Michael Sherman JD recently retired from his position as a Managing Director at Barclays Plc, where he had worked since 2008. Previously he was a Managing Director at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman has significant experience in healthcare finance, most recently assisting on a $450 million convertible transaction for Neurocrine Biosciences. He has worked on successful financial transactions for Teva Pharmaceutical Industries, Amgen Inc., Cubist Pharmaceuticals, Merck & Co., and Cardinal Health, among other companies. After graduating from the University of Pennsylvania, Michael Sherman received his JD, cum laude, from the Harvard Law School.
Richard J. Berman
Richard J. Berman currently serves as director of four public healthcare companies: Catasys Inc, Advaxis Inc., Immuron Ltd, and Cryoport Inc. From 2006-2011, Mr. Berman was chairman of National Investment Managers, a company with $12 billion pension administration assets. Earlier, Mr. Berman worked at Goldman Sachs, served as Chairman and CEO of Internet Commerce Corp. (now Easylink Services) and as senior vice president of Bankers Trust Company, where he advised on more than 300 M&A transactions for a total of $4 billion and launched the M&A and Leveraged Buyout departments. Mr. Berman was also a director of the Stern School of Business at New York University, where he earned his BS and MBA degrees. Berman holds law degrees from Boston College and The Hague Academy of International Law.
Forward Looking Statements
This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.